Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (21 days) for reimbursement as a treatment option for the treatment of patients with CD20 positive non-Hodgkin's lymphoma. This indication is also generally for cyclophosphamide, doxorubicin, vincristine, and prednisolone as a treatment option for patients non-Hodgkin's lymphoma, and the treatment regimen notes that rituximab should be included for CD20+ patients.

This is written in the approval document as:

Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.

Reimbursement

Hospital

Citation

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days, 2024, version number 5a, NCCP National SACT Regimen, viewed 26/03/2026, https://healthservice.hse.ie/documents/6711/307_v5a_R_Chop_21_days.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-01-18	Health Service Executive	Indication approved for reimbursement.